# US 2015/0147388 A1 · Materials and Methods for Modulating immune Responses

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0147388 A1
- Document ID: US20150147388A1
- Status: Published application
- Kind: A1
- Application number: 14/117,122
- Filed: 2012-06-25
- Published: 2015-05-28
- Earliest claimed: 2011-06-23
- Assignees: University of Florida Research Foundation, Inc.
- Inventors: Clive Henry Wasserfall; Mark A. Atkinson; Benjamin George Keselowsky; Young Mee Yoon
- Web page: https://patentgrep.com/patent/US20150147388A1

## CPC

- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61K 38/193: {Colony stimulating factors [CSF]}
- A61K 39/0005: {Vertebrate antigens (from snakes A61K39/38)}
- A61K 39/35: Allergens
- A61K 47/34: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers (A61K47/10 takes precedence)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 35/00: Antineoplastic agents
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61K 2039/55555: {Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides materials and methods for modulating an immune response. In one embodiment, the present invention provides an initial artificial lymph-node homing environment, and a simultaneous, or subsequent, artificial spleen environment leading to the resolution of the activated immune responses. In one specific embodiment, the present invention can be used to prevent and/or treat pathogenic infection, cancer, allergenic reactions, and/or unwanted immune or auto-immune responses.

## Claims

### Claim 1

A method for inducing a protective immune response against a target antigen, autoantigen or allergen, wherein the method comprises administering, to a subject in need of such an immune response, a pro-inflammatory adjuvant and an anti-inflammatory adjuvant, wherein said method further comprises administering the target antigen, autoantigen or allergen.

### Claim 2 (depends on 1)

The method, according to claim 1, wherein the pro-inflammatory adjuvant comprises one or more of the following: aluminum hydroxide (Alum), lipopolysaccharides (LPS), cytosine-guanosine (CpG) oligonucleotide (CpG-ODN) sequences, polyinosinic:polycytidylic acid (poly IC), a pro-inflammatory cytokine, a CpG rich oligonucleotide, leukotriene, arachidonic acids, prostaglandins, an arachidonic acid-pathway activator, a cyclo-oxygenase-pathway activator, incomplete Freund's adjuvant, complete Freund's adjuvant, and Freund's adjuvant with muramyldipeptide (MDP).

### Claim 3 (depends on 1)

The method, according to claim 1, wherein the anti-inflammatory adjuvant comprises one or more of the following: hemoglobin:haptoglobin, hemin, heme:hemopexin, a nonsteroidal anti-inflammatory drug (NSAID), a triterpinoid, ethyl pyruvate (EP), a hemeoxygenase (HO-1)-pathway activator, an arachidonic acid-pathway inhibitor, and a COX-pathway inhibitor.

### Claim 4 (depends on 1)

The method, according to claim 1, wherein the anti-inflammatory adjuvant is administered after the pro-inflammatory adjuvant.

### Claim 5 (depends on 1)

The method, according to claim 1, wherein the pro-inflammatory adjuvant and the anti-inflammatory adjuvant are administered simultaneously.

### Claim 6 (depends on 1)

The method, according to claim 1, further comprising administering an immuno-modulating molecule that induces the migration of an immune cell.

### Claim 7 (depends on 6)

The method, according to claim 6, wherein the immuno-modulating molecule is selected from GM-CSF, G-CSF, or both.

### Claim 8 (depends on 1)

The method, according to claim 1, used to prevent or treat pathogenic infection, cancer, allergy, immune disease, and/or autoimmune disease.

### Claim 9 (depends on 1)

The method, according to claim 1, used to prevent or treat type 1 diabetes.

### Claim 10

A device for modulating an immune response in a subject, wherein said device comprises: a scaffold matrix made of biocompatible material, wherein the scaffold matrix comprises a pro-inflammatory agent, an anti-inflammatory agent, and an antigen, autoantigen, or allergen.

### Claim 11 (depends on 10)

The device, according to claim 10, wherein the scaffold matrix comprises a hydrogel.

### Claim 12 (depends on 10)

The device, according to claim 10, wherein the scaffold matrix further comprises an immuno-modulating molecule that induces the migration of an immune cell.

### Claim 13 (depends on 12)

The device, according to claim 12, wherein the immuno-modulating molecule is selected from GM-CSF, G-CSF, or both.

### Claim 14 (depends on 12)

The device according to claim 12, wherein the scaffold matrix further comprises a microparticle, wherein the microparticle encapsulates therein, at least: said antigen, autoantigen, or allergen, wherein the outer surface of the microparticle comprises one or more surface ligands that bind to the target immune cell.

### Claim 15 (depends on 14)

The device, according to claim 14, wherein the microparticle is made of materials comprising PLGA.

### Claim 16

A device for modulating an immune response in a subject, wherein said device comprises:
1) a pro-inflammatory composition comprising: a scaffold matrix comprising:
a) an immuno-modulating molecule that induces the migration of an immune cell,
b) a pro-inflammatory agent, and
c) a microparticle encapsulating therein, at least, an antigen, autoantigen, or allergen; and
2) an anti-inflammatory composition comprising a scaffold matrix, wherein the scaffold matrix comprises an anti-inflammatory agent;
wherein the outer surface of the microparticle comprises one or more surface ligands that bind to the target immune cell.

### Claim 17 (depends on 16)

The device, according to claim 16, wherein the anti-inflammatory composition is released after the pro-inflammatory composition is released.

### Claim 18 (depends on 16)

The device, according to claim 16, wherein the scaffold matrix is made of materials comprising hydrogel.

### Claim 19 (depends on 16)

The device, according to claim 16, wherein the immuno-modulating molecule is selected from GM-CSF, G-CSF, or both.

### Claim 20 (depends on 16)

The device, according to claim 16, wherein the immune cell is a dendritic cell.
